InvestSMART

PharmX Technologies Limited (ASX:PHX)

ALERT: Price-sensitive ASX Announcement for PHX
Current share price for PHX : $0.110 -0.035 (-24.14%)+
Announcement
Release
25 Feb 2026 8:27AM
Price at Release
$0.145
Full Release
download
Summary
PharmX Technologies Limited (ASX: PHX) reported its H1 FY26 results, highlighting a 3% revenue increase to $3.9 million compared to the previous period. The company achieved a positive EBITDA of $0.5 million amid significant development and marketing investments for the successful launch of the new PharmX Marketplace. The strategic alliance with Sigma Healthcare Limited (SIG) further strengthens PharmX's position as the preferred EDI service provider across Australia and New Zealand. The company continues to expand its supplier network, adding 19 new partners, and enhancing its digital platform capabilities, resulting in increased transaction volumes and improved gross margins. Looking ahead, PharmX aims to deepen pharmacy engagement and expand its market reach while maintaining its focus on technology infrastructure and analytics capabilities.
Key Points
  • Revenue of $3.9 million, up 3% from the previous period.
  • Positive EBITDA of $0.5 million.
  • Successful launch of PharmX Marketplace.
  • Strategic alliance with Sigma Healthcare Limited.
  • 19 new suppliers added, increasing network by 8%.
  • Gross margin improved to 84%, up 2%.
  • Closing cash position of $3.2 million.
  • Focus on expanding supplier network and enhancing digital platform.
  • Record month for GTV in December 2025, up 68%.
  • New Zealand supplier revenue increased by 54%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.